Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

544
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

1.3K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

1.0K
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
Pericarditis I: Introduction01:22

Pericarditis I: Introduction

758
Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...
758

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of performance of Spanish version of PURE-4 questionnaire for early identification of psoriatic arthritis after 1 year of follow-up in patients with psoriasis.

PloS one·2026
Same author

Barriers to optimal psoriasis care from patient and provider perspectives: A multinational survey.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

Actas dermo-sifiliograficas·2025
Same author

[Translated article] Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis.

Actas dermo-sifiliograficas·2024
Same author

[Translated article] Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients.

Actas dermo-sifiliograficas·2024
Same author

Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis.

The British journal of dermatology·2021

Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K

Psoriatic arthritis: an update.

A López-Ferrer1, A Laiz-Alonso2

  • 1Servicio de Dermatología, Hospital de la Sant Creu i Sant Pau, Barcelona, España.

Actas Dermo-Sifiliograficas
|March 29, 2014
PubMed
Summary
This summary is machine-generated.

This review highlights advances in understanding psoriatic arthritis pathogenesis, focusing on immune pathways and genetic susceptibility. It also discusses biomarkers for early diagnosis and treatment prediction, and novel therapeutic approaches.

Keywords:
Artritis psoriásicaMultidisciplinarMultidisciplinary focusPsoriasisPsoriatic arthritisTratamientoTreatment

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.5K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

2.2K

Related Experiment Videos

Last Updated: May 1, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.5K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

2.2K

Area of Science:

  • Immunology
  • Rheumatology
  • Genetics

Background:

  • Psoriatic arthritis (PsA) pathogenesis understanding has advanced.
  • Common inflammatory pathways, including the IL-12/IL-23 axis, are implicated.
  • Genetic factors influence PsA susceptibility and disease phenotype.

Purpose of the Study:

  • To review current understanding of psoriatic arthritis pathogenesis and clinical aspects.
  • To discuss the role of biomarkers in diagnosis, prognosis, and treatment response.
  • To examine the impact of treatments on new bone formation and screening strategies.

Main Methods:

  • Literature review of recent studies on psoriatic arthritis.
  • Analysis of research on inflammatory pathways and genetic associations.
  • Evaluation of data on biomarkers and treatment effects.

Main Results:

  • Identification of key inflammatory pathways (e.g., IL-12/IL-23 axis) and susceptibility genes.
  • Growing interest in biomarkers for early diagnosis, prognosis, and treatment prediction.
  • Differences noted in how DMARDs and biologics affect new bone formation in PsA.

Conclusions:

  • Advances in understanding PsA pathogenesis and clinical features necessitate updated reviews.
  • Biomarkers and improved screening methods are crucial for early detection and management.
  • Further research is needed on treatment effects on bone formation and multidisciplinary care protocols.